CA
NZ
UK
US
AU
IND
Last update at 2024-04-08T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Intellipharmaceutics Provides Operational Update
Wed 24 Jan 18, 01:00 PMIntellipharmaceutics Announces Receipt of Nasdaq Notice
Tue 05 Dec 17, 01:00 PMIntellipharmaceutics Announces Closing of US$4 Million Financing
Fri 13 Oct 17, 09:45 PMIntellipharmaceutics Announces US$4 Million Registered Direct Offering
Wed 11 Oct 17, 12:00 PMIntellipharmaceutics Announces Third Quarter 2017 Results
Tue 10 Oct 17, 09:20 PMIntellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA
Mon 25 Sep 17, 11:00 AMIntellipharmaceutics Appoints New Chief Financial Officer
Fri 01 Sep 17, 12:00 PM| Breakdown | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 | 2018-11-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 | 2018-11-30 |
| Income before tax | -2.88706M | -5.25934M | -3.35813M | -8.09001M | -13.74748M |
| Minority interest | - | - | - | - | - |
| Net income | -2.89239M | -5.14515M | -3.39097M | -8.08465M | -13.73889M |
| Selling general administrative | 0.56M | 1.25M | 2.15M | 4.17M | 3.48M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 0.07M | 0.00000M | 1.40M | 3.45M | 1.59M |
| Reconciled depreciation | 0.21M | 0.26M | 0.42M | 0.51M | 0.61M |
| Ebit | -2.85051M | -4.17308M | -4.67831M | -7.83495M | -13.32627M |
| Ebitda | -2.64445M | -3.91155M | -1.76293M | -7.31473M | -12.88810M |
| Depreciation and amortization | 0.21M | 0.26M | 2.92M | 0.52M | 0.44M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -2.85051M | -4.17308M | -4.67831M | -7.83495M | -13.32627M |
| Other operating expenses | 2.92M | 4.17M | 6.08M | 11.32M | 15.04M |
| Interest expense | 0.29M | 0.55M | 0.97M | 0.25M | 0.26M |
| Tax provision | 0.00534M | -0.11419M | 0.03M | -0.00536M | - |
| Interest income | 0.08M | 0.57M | 1.14M | 0.26M | 0.42M |
| Net interest income | -0.29162M | -0.54930M | -0.96965M | -0.23398M | -0.42981M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.00534M | -0.11419M | 0.03M | -0.00536M | -0.00859M |
| Total revenue | 0.07M | 0.00000M | 1.40M | 3.48M | 1.71M |
| Total operating expenses | 2.92M | 4.17M | 6.08M | 11.28M | 14.91M |
| Cost of revenue | - | 0.00000M | 0.00000M | 0.03M | 0.12M |
| Total other income expense net | -0.03655M | -1.08627M | 1.32M | -0.25506M | -0.42121M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -2.89239M | -5.14515M | -3.39097M | -8.08465M | -13.74748M |
| Net income applicable to common shares | -2.89239M | -5.14515M | -3.39097M | -8.08465M | -13.74748M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 | 2018-11-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 | 2018-11-30 |
| Total assets | 1.43M | 2.10M | 3.39M | 3.80M | 11.47M |
| Intangible assets | - | - | - | - | 0.01M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.02M | - | 0.12M | 0.16M | 0.59M |
| Total liab | 12.01M | 10.25M | 9.70M | 7.49M | 7.37M |
| Total stockholder equity | -10.57673M | -8.15522M | -6.31359M | -3.69222M | 4.10M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 5.92M | 4.55M | 3.48M | 1.83M | 0.58M |
| Common stock | 49.18M | 49.18M | 46.14M | 45.56M | 44.33M |
| Capital stock | 49.18M | 49.18M | 46.14M | 45.56M | 44.33M |
| Retained earnings | -105.13410M | -102.24170M | -97.09655M | -93.70558M | -85.62094M |
| Other liab | - | - | - | - | 2.06M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | 0.00000M |
| Cash | 0.08M | 0.77M | 0.20M | 0.06M | 6.64M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 12.01M | 10.25M | 9.70M | 7.49M | 5.31M |
| Current deferred revenue | - | - | - | - | 0.30M |
| Net debt | 2.24M | 1.15M | 1.91M | 1.84M | -4.85152M |
| Short term debt | 2.33M | 1.92M | 2.11M | 1.90M | 1.79M |
| Short long term debt | 2.16M | 1.92M | 1.96M | 1.90M | 1.79M |
| Short long term debt total | 2.33M | 1.92M | 2.11M | 1.90M | 1.79M |
| Other stockholder equity | 45.10M | 44.63M | 44.35M | 44.17M | 45.11M |
| Property plant equipment | 0.94M | 0.99M | 1.90M | 2.27M | 2.74M |
| Total current assets | 0.49M | 1.10M | 1.48M | 1.52M | 8.72M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -10.57673M | -8.15678M | -6.31671M | -3.69845M | 4.09M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.39M | 0.27M | 1.05M | 0.95M | 1.24M |
| Long term debt | - | - | - | - | - |
| Inventory | - | 0.00000M | 0.11M | 0.35M | 0.25M |
| Accounts payable | 3.76M | 3.78M | 4.10M | 3.76M | 2.64M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.28M | 0.28M | 0.28M | 0.28M | 0.28M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 46.14M | 45.56M | 44.33M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | 2.27M | 2.76M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.94M | 0.99M | 1.91M | 2.27M | 2.76M |
| Capital lease obligations | 0.17M | 0.00000M | 0.16M | - | - |
| Long term debt total | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Breakdown | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 | 2018-11-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-11-30 | 2021-11-30 | 2020-11-30 | 2019-11-30 | 2018-11-30 |
| Investments | 0.50M | 0.00000M | 0.03M | -0.01447M | -0.10118M |
| Change to liabilities | 1.34M | 0.98M | 2.03M | 0.22M | -0.55631M |
| Total cashflows from investing activities | 0.50M | 0.50M | 0.03M | -0.01447M | -0.10118M |
| Net borrowings | 0.20M | 0.20M | 0.20M | 0.07M | 0.50M |
| Total cash from financing activities | 0.20M | 3.03M | 3.03M | 0.10M | 17.35M |
| Change to operating activities | -0.07782M | -0.10355M | 0.00238M | 0.43M | -0.36170M |
| Net income | -2.89239M | -5.14515M | -3.39097M | -8.08465M | -13.74748M |
| Change in cash | -0.68822M | 0.57M | 0.14M | -6.57726M | 4.74M |
| Begin period cash flow | 0.77M | 0.20M | 0.06M | 6.64M | 1.90M |
| End period cash flow | 0.08M | 0.77M | 0.20M | 0.06M | 6.64M |
| Total cash from operating activities | -1.38822M | -2.46133M | 0.11M | -6.66368M | -12.50896M |
| Issuance of capital stock | 0.00000M | 3.07M | 0.00000M | 0.00000M | 19.64M |
| Depreciation | 0.21M | 0.26M | 0.42M | 0.51M | 0.61M |
| Other cashflows from investing activities | 0.50M | 0.00000M | 0.03M | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 0.00000M | 0.00000M | -0.09748M | -0.13598M |
| Change to account receivables | -0.00060M | 0.57M | -0.38918M | 0.06M | 0.45M |
| Sale purchase of stock | 0.00000M | 3.07M | 0.00000M | 0.03M | 19.77M |
| Other cashflows from financing activities | 0.50M | -0.03822M | 0.03M | 0.56M | -2.28995M |
| Change to netincome | - | 1.00M | 1.41M | 0.29M | 1.23M |
| Capital expenditures | 0.00000M | 0.00000M | 0.00387M | 0.01M | 0.10M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 1.27M | 1.42M | 1.68M | 0.62M | -0.60344M |
| Stock based compensation | -0.05020M | 0.01M | 0.07M | 0.26M | 0.93M |
| Other non cash items | 0.08M | 1.08M | 1.34M | 0.04M | 0.30M |
| Free cash flow | -1.38822M | -2.46133M | 0.11M | -6.67815M | -12.61014M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IPCI Intellipharmaceutics International Inc |
- -% | 0.08 | - | - | 2.38 | - | 5.09 | -2.417 |
| FRX Fennec Pharmaceuticals Inc |
0.49 5.73% | 9.04 | 58.90 | 212.77 | 3.27 | 57.98 | 2.14 | 15.89 |
| MDNA Medicenna Therapeutics Corp |
0.06 6.00% | 1.06 | - | 204.08 | - | 6.92 | -6.1093 | |
| EPRX Eupraxia Pharmaceuticals Inc |
0.10 1.88% | 5.42 | - | - | - | 7.62 | -3.8823 | |
| ONC Oncolytics Biotech Inc |
- -% | 0.72 | - | - | - | 6.21 | -2.4457 |
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.
30 Worcester Road, Toronto, ON, Canada, M9W 5X2
| Name | Title | Year Born |
|---|---|---|
| Dr. Isa Odidi MBA, Ph.D. | Co-Founder, Chairman, CEO & Co-Chief Scientific Officer | 1958 |
| Dr. Amina Odidi Ph.D. | Pres, COO, Co-Chief Scientific Officer, Acting CFO & Exec. Director | 1960 |
| Dr. Patrick N. Yat Ph.D. | Vice-Pres of Chemistry & Analytical Services | 1958 |
| Fazayill Shaideen | Controller | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...